Senior VP
Intellia Therapeutics
Cambridge, Massachusetts, United States
Yuanxin Xu, M.D., Ph.D.
Senior Vice President, Early Development and Translational Medicine
Yuanxin is Sr. VP at Intellia to advance in vivo and ex vivo gene editing therapeutic development. She serves as Head of Early Development and Translational Medicine since January 2020, responsible for pharmacology, toxicology, DMPK, and bioanalysis. She joins Intellia from Alnylam (5 years) as Sr. Director of Bioanalytical Sciences for RNAi therapeutic development to treat genetic diseases, including patisiran, the 1st approved RNAi therapy. During her 13 years with Clinical Laboratory Sciences at Genzyme/Sanofi, she was most recently Sr. Director and supported clinical studies and approvals of biologics, antibodies, small molecules, as well as cell and gene therapies. Her early experience was at BioTransplant-Immerge (9 years) investigating xenogeneic and HLA mismatched allogeneic stem cell and organ transplantation and induction of immune tolerance. Yuanxin received her B.M. (M.D. equivalent) from Beijing Medical University (now Peking University Health Science) and her Ph.D. in Biochemistry from Iowa State University.
Disclosure information not submitted.
Tuesday, April 25, 2023
9:30 AM – 10:00 AM ET